A DNA self-test will soon counter the United States, indeed the health authorities have to authorize the sale of a DNA test that will allow its users whether his children may be reached Bloom syndrome , a rare genetic disease. This is a first step to liberalize an industry that currently defy regulators.

The kit is developed by the biotechnology group 23andme, the internet giant Google is one of the investors, and that the US drug agency, the FDA banned in November 2013 to market in the state of DNA tests for determine disease risk.

A new self-test on sale in the US

The FDA had considered that such a product, based on a sample of saliva and expected contingencies including information on diabetes or breast cancer, might drive users to undertake treatments unfounded or, conversely, ” to ignore a real risk “by giving a negative result.

Created and directed by Anne Wojcicki, the former wife of Google co-founder, is now marketed 23andme test of its kind in Canada and the United Kingdom, but merely sell kits to family referred to the United States. The FDA has now taken a small step towards the liberalization of such tests, allowing Thursday 23andme, which recently announced partnerships with Roche and Pfizer, to sell a health related product.

Measuring the FDA is limited because the test in question is not intended to assess the risks to the user himself but by his children, and he provides a rare disease, Bloom syndrome. This inherited disease causes growth retardation, infertility in men and high risk of developing cancer.

“FDA believes that, in many circumstances, the client does not need to go through a health professional for direct access to personal information about its genome,” said Alberto Gutierrez, an official of the agency, quoted in a statement. “These tests are able to provide users with information on possible changes in their genes that can be passed on to their children,” he added.